No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
CC240726C26000
- 0.03
- -0.27-90.00%
15min DelayClose Jul 19 15:59 ET
0.03High0.03Low
0.03Open0.30Pre Close1 Volume17 Open Interest26.00Strike Price3.00Turnover53.56%IV10.86%PremiumJul 26, 2024Expiry Date0.00Intrinsic Value100Multiplier4DDays to Expiry0.03Extrinsic Value100Contract SizeAmericanOptions Type0.0512Delta0.0735Gamma782.67Leverage Ratio-0.0144Theta0.0002Rho40.07Eff Leverage0.0028Vega
Intraday
- 5D
- Daily
News
Morgan Stanley Maintains The Chemours(CC.US) With Hold Rating, Maintains Target Price $30
Morgan Stanley analyst Vincent Andrews maintains $The Chemours(CC.US)$ with a hold rating, and maintains the target price at $30.According to TipRanks data, the analyst has a success rate of 66.4%
Chemours Announces Dates for Second Quarter 2024 Earnings Release and Webcast Conference Call
The Chemours Company ("Chemours" or "the Company") (NYSE:CC) today announced that the Company expects to issue its second quarter 2024 financial results after market close on Thursday, August 1, 2024. The Company
Chemours to Benefit From Regulation on Refrigerants as Demand Improves, UBS Says
Chemours' (CC) low share valuation and conservative estimates are expected to pivot as earnings in TiO2 return to normal and demand for refrigerants improves by 2025, UBS said in a note Tuesday."We
Express News | Chemours Shares Are Trading Higher After UBS Upgraded the Stock From Neutral to Buy and Raised Its Price Target From $28 to $30
Chemours Price Target Raised to $30.00/Share From $28.00 by UBS
Chemours Price Target Raised to $30.00/Share From $28.00 by
Chemours Raised to Buy From Neutral by UBS
Chemours Raised to Buy From Neutral by
Comments
$The Chemours(CC.US$
Unusual Options Activity
There was an unusual amount of activity on the options chain for The Chemours company. Most of the activity was on the put side. You can see this in the heavily skewed put to call ratio in the picture directly below. A lopsided put/call ratio like this doesn't show the full picture. We need to find out if the puts were bought or sold to know if the activity was bullish or bear...
Unusual Options Activity
There was an unusual amount of activity on the options chain for The Chemours company. Most of the activity was on the put side. You can see this in the heavily skewed put to call ratio in the picture directly below. A lopsided put/call ratio like this doesn't show the full picture. We need to find out if the puts were bought or sold to know if the activity was bullish or bear...
+6
22
10
Morning Movers
Gapping up
$Estee Lauder(EL.US$ Shares soared over 3% following an upgrade to buy from neutral by Bank of America, which referenced the company's profitability recovery efforts, new products, and growing market share in the prestige beauty sector.
$Allstate(ALL.US$ The insurance stock climbed 0.9% after HSBC raised its rating to buy from hold, with analyst Vikram Gandhi commending the company's "decisive management...
Gapping up
$Estee Lauder(EL.US$ Shares soared over 3% following an upgrade to buy from neutral by Bank of America, which referenced the company's profitability recovery efforts, new products, and growing market share in the prestige beauty sector.
$Allstate(ALL.US$ The insurance stock climbed 0.9% after HSBC raised its rating to buy from hold, with analyst Vikram Gandhi commending the company's "decisive management...
20
The revelation of material weaknesses in Chemours' financial reporting and the manipulation of vendor payments and receivables by top executives could negatively impact investor confidence and the company's stock price.
Chemours' ongoing investigation and executive suspension could hurt investor confidence and stock price, despite a narrower Q4 loss and higher revenue.
1
Read more